Literature DB >> 2427024

Tolerance to fenfluramine anorexia: fact or fiction?

N E Rowland, J Carlton.   

Abstract

Recent findings in this laboratory with regard to tolerance to fenfluramine anorexia are reviewed with respect to generality of the behavioural phenomenon. A systematic relationship between initial body weight and fenfluramine-induced weight change in rats is described. The possible roles of peripheral factors in fenfluramine anorexia and tolerances, including gastric emptying and peripheral serotonin, are discussed. The role of central factors is also considered. It appears that fenfluramine, and possibly other anorectic agents have multiple sites of action and affect multiple behaviours. Some clinical implications are noted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427024     DOI: 10.1016/s0195-6663(86)80053-8

Source DB:  PubMed          Journal:  Appetite        ISSN: 0195-6663            Impact factor:   3.868


  6 in total

1.  Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence.

Authors:  J McGuirk; R Muscat; P Willner
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Proceedings of the British Pharmacological Society. 6th-8th January, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

3.  Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Authors:  J A Suyama; M L Banks; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

4.  Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats.

Authors:  S P Vickers; K R Benwell; R H Porter; M J Bickerdike; G A Kennett; C T Dourish
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist.

Authors:  Akane Ishihara; Akio Kanatani; Megumu Okada; Masayasu Hidaka; Takeshi Tanaka; Satoshi Mashiko; Akira Gomori; Tetsuya Kanno; Mikiko Hata; Maki Kanesaka; Yushin Tominaga; Naga-aki Sato; Masahiko Kobayashi; Takashi Murai; Keiko Watanabe; Yasuyuki Ishii; Takahiro Fukuroda; Takehiro Fukami; Masaki Ihara
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 6.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.